ANGPTL2 activity in cardiac pathologies accelerates heart failure by perturbing cardiac function and energy metabolism

[1]  T. Ninomiya,et al.  Serum Angiopoietin–Like Protein 2 Is a Novel Risk Factor for Cardiovascular Disease in the Community: The Hisayama Study , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[2]  K. Naruse,et al.  Induced NCX1 overexpression attenuates pressure overload-induced pathological cardiac remodelling. , 2016, Cardiovascular research.

[3]  M. Suematsu,et al.  Glutamine Oxidation Is Indispensable for Survival of Human Pluripotent Stem Cells. , 2016, Cell metabolism.

[4]  Y. Oike,et al.  Angiopoietin-like protein 2 increases renal fibrosis by accelerating transforming growth factor-β signaling in chronic kidney disease. , 2016, Kidney international.

[5]  F. Wang,et al.  [Role of calcineurin-nuclear factor of activated T cells signaling pathway in myoblast apoptosis induced by cyclic tensile strain]. , 2015, Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology.

[6]  Yen-Wen Wu,et al.  Serum Angiopoietin-Like Protein 2 Concentrations Are Independently Associated with Heart Failure , 2015, PloS one.

[7]  R. Hui,et al.  MicroRNA-221 inhibits autophagy and promotes heart failure by modulating the p27/CDK2/mTOR axis , 2014, Cell Death and Differentiation.

[8]  M. Oshimura,et al.  Reprogramming Suppresses Premature Senescence Phenotypes of Werner Syndrome Cells and Maintains Chromosomal Stability over Long-Term Culture , 2014, PloS one.

[9]  Vassilios J. Bezzerides,et al.  Abstract 238: miR-222 is Necessary for Exercise-induced Cardiac Growth and Protects Against Pathological Cardiac Remodeling , 2014 .

[10]  B. Schroen,et al.  P69The microRNA-221/222 family is differentially regulated in cardiac disease and counteracts pressure overload-induced cardiac remodeling in mice , 2014 .

[11]  M. Nakano,et al.  Serum ANGPTL2 Levels Reflect Clinical Features of Breast Cancer Patients: Implications for the Pathogenesis of Breast Cancer Metastasis , 2014, The International journal of biological markers.

[12]  Y. Oike,et al.  Diverse roles of ANGPTL2 in physiology and pathophysiology , 2014, Trends in Endocrinology & Metabolism.

[13]  G. Santulli.  Angiopoietin-Like Proteins: A Comprehensive Look , 2014, Front. Endocrinol..

[14]  N. Mochizuki,et al.  The Secreted Protein ANGPTL2 Promotes Metastasis of Osteosarcoma Cells Through Integrin α5β1, p38 MAPK, and Matrix Metalloproteinases , 2014, Science Signaling.

[15]  Y. Oike,et al.  The angiotensin II AT1 receptor-associated protein Arap1 is involved in sepsis-induced hypotension , 2013, Critical Care.

[16]  J. Molkentin.  Parsing Good Versus Bad Signaling Pathways in the Heart: Role of Calcineurin–Nuclear Factor of Activated T-Cells , 2013, Circulation research.

[17]  S. Takanashi,et al.  Perivascular adipose tissue-secreted angiopoietin-like protein 2 (Angptl2) accelerates neointimal hyperplasia after endovascular injury. , 2013, Journal of molecular and cellular cardiology.

[18]  A. Rosenzweig,et al.  Can Exercise Teach Us How to Treat Heart Disease? , 2012, Circulation.

[19]  G. Lopaschuk,et al.  Agonist-Induced Hypertrophy and Diastolic Dysfunction Are Associated With Selective Reduction in Glucose Oxidation: A Metabolic Contribution to Heart Failure With Normal Ejection Fraction , 2012, Circulation. Heart failure.

[20]  R. Hui,et al.  MiR‐221 promotes cardiac hypertrophy in vitro through the modulation of p27 expression , 2012, Journal of cellular biochemistry.

[21]  Y. Oike,et al.  Macrophage-Derived Angiopoietin-Like Protein 2 Accelerates Development of Abdominal Aortic Aneurysm , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[22]  M. Nakano,et al.  Tumor cell-derived angiopoietin-like protein ANGPTL2 is a critical driver of metastasis. , 2012, Cancer research.

[23]  S. Hirakawa,et al.  Angiopoietin-like protein 2 is an important facilitator of inflammatory carcinogenesis and metastasis. , 2011, Cancer research.

[24]  Shinya Yamanaka,et al.  Efficient and Scalable Purification of Cardiomyocytes from Human Embryonic and Induced Pluripotent Stem Cells by VCAM1 Surface Expression , 2011, PloS one.

[25]  T. Prolla,et al.  Mitochondrial Oxidative Stress Mediates Angiotensin II–Induced Cardiac Hypertrophy and G&agr;q Overexpression–Induced Heart Failure , 2011, Circulation research.

[26]  Volker Adams,et al.  Cardiovascular Effects of Exercise Training: Molecular Mechanisms , 2010, Circulation.

[27]  M. Kasuga,et al.  Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance. , 2009, Cell metabolism.

[28]  S. Miyano,et al.  Ligand-based gene expression profiling reveals novel roles of glucocorticoid receptor in cardiac metabolism. , 2009, American journal of physiology. Endocrinology and metabolism.

[29]  I. Kasman,et al.  PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. , 2009, Cancer cell.

[30]  L. Opie,et al.  Metabolic mechanisms in heart failure. , 2007, Circulation.

[31]  G. Jennings,et al.  DIFFERENCES BETWEEN PATHOLOGICAL AND PHYSIOLOGICAL CARDIAC HYPERTROPHY: NOVEL THERAPEUTIC STRATEGIES TO TREAT HEART FAILURE , 2007, Clinical and experimental pharmacology & physiology.

[32]  I. Komuro,et al.  p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload , 2007, Nature.

[33]  I. Shiojima,et al.  Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. , 2006, Genes & development.

[34]  Peter C Austin,et al.  Outcome of heart failure with preserved ejection fraction in a population-based study. , 2006, The New England journal of medicine.

[35]  T. Otsuki,et al.  Exercise training improves aging-induced downregulation of VEGF angiogenic signaling cascade in hearts. , 2006, American journal of physiology. Heart and circulatory physiology.

[36]  R. Schwartz,et al.  Cardiac-Specific Deletion of Gata4 Reveals Its Requirement for Hypertrophy, Compensation, and Myocyte Viability , 2006, Circulation research.

[37]  T. Suda,et al.  Cooperative interaction of Angiopoietin-like proteins 1 and 2 in zebrafish vascular development. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Christoph Handschin,et al.  Metabolic control through the PGC-1 family of transcription coactivators. , 2005, Cell metabolism.

[39]  S. Umemura,et al.  The novel angiotensin II type 1 receptor (AT1R)‐associated protein ATRAP downregulates AT1R and ameliorates cardiomyocyte hypertrophy , 2005, FEBS letters.

[40]  Frank J Giordano,et al.  Oxygen, oxidative stress, hypoxia, and heart failure. , 2005, The Journal of clinical investigation.

[41]  A. Itai,et al.  A novel IKKbeta inhibitor stimulates adiponectin levels and ameliorates obesity-linked insulin resistance. , 2004, Biochemical and biophysical research communications.

[42]  J. Huss,et al.  Nuclear receptor signaling and cardiac energetics. , 2004, Circulation research.

[43]  James M. Allen,et al.  Systemic delivery of genes to striated muscles using adeno-associated viral vectors , 2004, Nature Medicine.

[44]  Robert G Weiss,et al.  Is the failing heart energy starved? On using chemical energy to support cardiac function. , 2004, Circulation research.

[45]  D. Kass,et al.  What Mechanisms Underlie Diastolic Dysfunction in Heart Failure? , 2004, Circulation research.

[46]  Stephan von Haehling,et al.  Inflammatory mediators in chronic heart failure: an overview , 2004, Heart.

[47]  C. Croce,et al.  Mechanism of Enhanced Cardiac Function in Mice with Hypertrophy Induced by Overexpressed Akt* , 2003, Journal of Biological Chemistry.

[48]  S. Orlov,et al.  Type 1 angiotensin II receptor-associated protein ARAP1 binds and recycles the receptor to the plasma membrane. , 2003, Biochemical and biophysical research communications.

[49]  Pamela S Douglas,et al.  Acc/aha/ase 2003 Guideline Update for the Clinical Application of Echocardiography: Summary Article a Report of the American College of Cardiology/american Heart Association Task Force on Practice Guidelines (acc/aha/ase Committee to Update the 1997 Guidelines for the Clinical Application of Echocar , 2003 .

[50]  D. Faxon,et al.  ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echoca , 2003, Journal of the American College of Cardiology.

[51]  D. J. Veldhuisen,et al.  The Imbalance Between Oxygen Demand and Supply as a Potential Mechanism in the Pathophysiology of Heart Failure: The Role of Microvascular Growth and Abnormalities , 2003, Microcirculation.

[52]  P. Doevendans,et al.  Requirement of Nuclear Factor of Activated T-cells in Calcineurin-mediated Cardiomyocyte Hypertrophy* , 2002, The Journal of Biological Chemistry.

[53]  M. Chandler,et al.  Energy Metabolism in the Normal and Failing Heart: Potential for Therapeutic Interventions , 2002, Heart Failure Reviews.

[54]  D. Kelly,et al.  p38 Mitogen-activated Protein Kinase Activates Peroxisome Proliferator-activated Receptor α , 2001, The Journal of Biological Chemistry.

[55]  S. Sasayama,et al.  Calcineurin-GATA4 Pathway Is Involved in β-Adrenergic Agonist-responsive Endothelin-1 Transcription in Cardiac Myocytes* , 2001, The Journal of Biological Chemistry.

[56]  E. Lakatta,et al.  Culture and adenoviral infection of adult mouse cardiac myocytes: methods for cellular genetic physiology. , 2000, American journal of physiology. Heart and circulatory physiology.

[57]  K. Chien,et al.  Stress Pathways and Heart Failure , 1999, Cell.

[58]  E. Olson,et al.  Cardiac hypertrophy: sorting out the circuitry. , 1999, Current opinion in genetics & development.

[59]  B. Lorell,et al.  Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. , 1993, Circulation research.

[60]  C. Stevens,et al.  Aquaporin 4 and glymphatic flow have central roles in brain fluid homeostasis , 2021, Nature Reviews Neuroscience.

[61]  J. Gulick,et al.  Isolation and characterization of the mouse cardiac myosin heavy chain genes. , 1991, The Journal of biological chemistry.

[62]  J. Gwathmey,et al.  Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure. , 1990, Circulation.

[63]  C. Kawai,et al.  Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. , 1980, British heart journal.

[64]  HisaoOgawa,et al.  Role of Endothelial Cell–Derived Angptl2 in Vascular Inflammation Leading to Endothelial Dysfunction and Atherosclerosis Progression , 2014 .

[65]  T. Murohara,et al.  Usefulness of serum cardiac troponins T and I to predict cardiac molecular changes and cardiac damage in patients with hypertrophic cardiomyopathy. , 2013, International heart journal.

[66]  吉田 陽子.  p53-induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure , 2013 .

[67]  G. Fonarow,et al.  Epidemiology and risk profile of heart failure , 2011, Nature Reviews Cardiology.

[68]  P. Mahadevan,et al.  An overview , 2007, Journal of Biosciences.

[69]  E. Levin,et al.  Estrogen Inhibits Cardiomyocyte Hypertrophy in Vitro : ANTAGONISM OF CALCINEURIN-RELATED HYPERTROPHY THROUGH INDUCTION OF MCIP1* , 2005 .

[70]  G. Dorn,et al.  Cytoplasmic signaling pathways that regulate cardiac hypertrophy. , 2001, Annual review of physiology.

[71]  S. Katsuki.  [Hisayama study]. , 1971, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.